Oral Estradiol Cost in Arkansas 2026

What Does Oral Estradiol Actually Cost in Arkansas Right Now?

The average cash-pay price for a 30-day supply of generic oral estradiol at Arkansas retail pharmacies in 2026 is approximately $15. The manufacturer list price sits near $40 per month, but generic competition has driven retail prices well below that ceiling for most patients who pay without insurance.

Generic oral estradiol (estradiol USP tablets) has been available in strengths of 0.5 mg, 1 mg, and 2 mg since multiple manufacturer approvals cleared the FDA review process. Because the active pharmaceutical ingredient is off-patent and manufactured by several companies, pharmacy benefit managers and retail chains routinely price the drug at $10 to $20 per month on cash-pay discount programs. GoodRx, RxSaver, and similar platforms can push that figure even lower at high-volume pharmacies in Little Rock, Fayetteville, Fort Smith, and Jonesboro. [1][2]

Oral estradiol is FDA-approved for moderate-to-severe vasomotor symptoms of menopause, vulvar and vaginal atrophy, hypoestrogenism due to hypogonadism or castration, and female hypogonadism. [3] The Women's Health Initiative (WHI, JAMA 2002, N=16,608) remains the largest randomized trial of hormone therapy and found that conjugated equine estrogen reduced hip fracture risk by 34% and colorectal cancer risk by 37% in the estrogen-only arm, while the combined estrogen-progestin arm raised invasive breast cancer incidence by 26% relative to placebo. [4] Prescribers use that risk-benefit data to individualize oral estradiol therapy, choosing the lowest effective dose for the shortest necessary duration. [5]

Price transparency matters for adherence. A 2022 analysis published in the Journal of Managed Care and Specialty Pharmacy found that out-of-pocket costs above $25 per month for hormone therapy were independently associated with early discontinuation in women aged 45 to 64. [6] Keeping monthly spend at or below the Arkansas retail average of $15 reduces that discontinuation risk meaningfully.

Arkansas Medicaid Coverage for Oral Estradiol

Arkansas Medicaid (Arkansas DHS / Arkansas Medicaid) covers oral estradiol for members diagnosed with moderate-to-severe vasomotor symptoms of menopause, but the drug is subject to a Limited Prior Authorization (PA) requirement. [7]

To obtain PA approval, prescribers typically must document the clinical indication (e.g., menopausal status confirmed by FSH above 40 mIU/mL or surgical menopause), the absence of contraindications listed in the FDA label (including undiagnosed vaginal bleeding, known estrogen-dependent neoplasia, active deep vein thrombosis, or prior stroke), and the patient's current symptom severity. [3][8] Once approved, the PA is generally valid for 12 months and renewable annually with clinical documentation.

The Endocrine Society's 2015 clinical practice guideline on menopause states: "Menopausal hormone therapy (MHT) is the most effective treatment for vasomotor symptoms and is appropriate for healthy symptomatic women who are within 10 years of menopause onset or under age 60." [9] Arkansas Medicaid PA criteria broadly reflect that guidance, meaning the majority of appropriately referred patients should qualify.

If a PA request is denied, Arkansas Medicaid members have the right to appeal through the DHS Office of Appeals and Hearings. A prescriber letter citing the Endocrine Society guideline and WHI reanalysis data (notably the Manson et al. reanalysis in NEJM 2013 showing timing-dependent risk) strengthens an appeal substantially. [10]

Dual-eligible Medicare-Medicaid enrollees in Arkansas should also check their Part D plan formulary, as most Part D plans tier generic estradiol at $0 to $10 under the Inflation Reduction Act drug pricing provisions that took effect in 2024. [11]

Compounded Oral Estradiol in Arkansas: Legality and Pricing

Compounded oral estradiol is legal in Arkansas when prepared by a 503A pharmacy operating under a valid patient-specific prescription from a licensed prescriber. [12]

The distinction between 503A and 503B facilities matters for patients. A 503A pharmacy compounds for individual patients and does not require FDA registration, but it must comply with USP standards and Arkansas State Board of Pharmacy rules. A 503B outsourcing facility mass-produces compounded drugs and requires full FDA registration. Oral estradiol compounded for menopausal symptom management is typically dispensed through 503A pharmacies under patient-specific prescriptions. [13]

The North American Menopause Society (NAMS) published a 2022 position statement noting: "The available data do not support the superiority of compounded hormones over FDA-approved hormone therapies in terms of efficacy or safety." [14] That position is worth understanding. Compounded oral estradiol may offer flexibility in dosing increments (e.g., 0.25 mg micro-doses not available commercially) or avoidance of certain excipients for patients with documented allergies. However, batch-to-batch potency variability is a real clinical concern. [15]

Pricing for compounded oral estradiol through Arkansas 503A pharmacies ranges from $0 (when dispensed through specific integrative medicine or telehealth programs that absorb the cost) to approximately $15 to $30 per month depending on the compounding pharmacy, dose, and whether any discount program applies. [16] Some telehealth platforms operating in Arkansas include compounded estradiol as part of a subscription-based HRT program at no additional per-prescription charge.

Insurance Coverage for Oral Estradiol in Arkansas

Most commercial insurance plans sold on the Arkansas Health Insurance Marketplace (ACA plans) and most employer-sponsored plans cover generic oral estradiol, typically at Tier 1 or Tier 2, meaning a $0 to $20 copay per month. [17]

The ACA requires non-grandfathered plans to cover preventive services rated A or B by the U.S. Preventive Services Task Force (USPSTF) at no cost-sharing. [18] The USPSTF recommends against routine use of combined estrogen-progestin therapy to prevent chronic conditions in postmenopausal women, but that recommendation does not restrict coverage for symptomatic treatment of vasomotor symptoms, which remains a covered benefit under most plan designs. [19]

Arkansas Blue Cross Blue Shield, QualChoice, and Ambetter (the three largest individual market insurers in Arkansas as of 2025) each list oral estradiol generics on their formularies at Tier 1 for most plan types. Patients should verify their specific plan's formulary using the SBC (Summary of Benefits and Coverage) document or by calling the member services number on their insurance card.

Medicare Part D plans covering oral estradiol in Arkansas: most formularies tier generic estradiol at $0 to $10 under the standard benefit structure. The CMS Medicare Plan Finder tool at medicare.gov allows Arkansas beneficiaries to compare Part D plans by formulary cost for specific drugs. [20]

For patients whose plans impose a deductible period during which they pay full list price, manufacturer savings cards and pharmacy discount programs (described below) can offset out-of-pocket spending materially.

How to Get the Lowest Possible Price on Oral Estradiol in Arkansas

Several layered strategies can reduce the monthly cost of oral estradiol to single digits or zero for Arkansas residents.

Pharmacy discount programs. GoodRx, RxSaver, and Cost Plus Drugs (Mark Cuban's transparent-pricing pharmacy) each list oral estradiol. Cost Plus Drugs listed 1 mg estradiol tablets (90-count) at under $7 as of mid-2025. [21] That works out to roughly $2.30 per month for patients taking 1 mg daily. Patients pay with a discount card or through the Cost Plus platform directly, bypassing insurance entirely when the cash price is lower than the copay.

Manufacturer patient assistance. Several generic manufacturers offer PAP (Patient Assistance Program) enrollment for patients with household incomes below 200% of the federal poverty level. The NeedyMeds database at needymeds.org lists current program eligibility for oral estradiol generics. [22]

$4 generic lists. Walmart, Kroger, and Walgreens each maintain $4 to $10 generic lists that include oral estradiol at major Arkansas store locations. Patients should confirm current pricing at their nearest location, as formulary inclusions vary by chain contract cycle.

Telehealth platform bundles. Several telehealth providers licensed in Arkansas bundle the cost of compounded estradiol into a monthly subscription (typically $20 to $75 per month total), which effectively reduces the per-medication cost. Compare total subscription cost against the $15 retail cash price before enrolling.

FSA and HSA. Oral estradiol is an eligible FSA/HSA expense under IRS guidelines, meaning pre-tax dollars can be used for purchase. [23] For a patient in the 22% federal tax bracket, an FSA effectively reduces the $15 retail price to approximately $11.70.

Telehealth Prescribing of Oral Estradiol in Arkansas

Telehealth prescribing of oral estradiol is permitted in Arkansas under current telemedicine law. Arkansas Act 1009 of 2017 and subsequent amendments authorize licensed Arkansas physicians, APRNs, and PAs to prescribe Schedule-exempt medications (estradiol is not a controlled substance) via synchronous audio-video telehealth visits. [24]

The Ryan Haight Online Pharmacy Consumer Protection Act does not restrict prescribing of non-controlled substances, so oral estradiol can be prescribed after a telehealth encounter without requiring an in-person visit first. [25] Prescribers must still conduct a clinically appropriate evaluation, including history of cardiovascular disease, personal or family history of hormone-sensitive cancers, and current medications that interact with estrogen (notably CYP3A4 inducers such as rifampin, which can reduce estradiol levels by up to 40%). [26]

Arkansas-based telehealth platforms and national platforms with Arkansas licensure (including HealthRX) can evaluate patients, issue prescriptions, and coordinate dispensing through local or mail-order pharmacies. Turnaround from initial consultation to medication receipt is typically 2 to 5 business days for standard pharmacy fills.

Clinical Dosing and Safety Overview for Arkansas Prescribers and Patients

The FDA-approved dosing range for oral estradiol for vasomotor symptoms is 0.5 mg to 2 mg once daily. [3] Clinical practice typically starts at 1 mg daily, with titration to 2 mg if symptom control is inadequate after 8 to 12 weeks, or a step-down to 0.5 mg once symptoms are controlled. [9]

Oral estradiol undergoes first-pass hepatic metabolism, producing elevated levels of estrone and estrone sulfate relative to transdermal delivery. This metabolic difference is clinically significant for patients with hypertriglyceridemia: oral estradiol raises triglycerides by approximately 15 to 25%, while transdermal estradiol does not. [27] The Menopause Society (formerly NAMS) 2023 position statement on hormone therapy notes that transdermal routes may carry a lower venous thromboembolism (VTE) risk than oral routes, citing observational data from the E3N cohort (N=80,308) showing an odds ratio of 1.7 for VTE with oral estradiol versus 1.1 for transdermal. [28][29]

For women with an intact uterus, oral estradiol must be combined with a progestogen to prevent endometrial hyperplasia. The WHI estrogen-only arm (conjugated equine estrogen, N=10,739) was conducted exclusively in women with prior hysterectomy precisely because unopposed estrogen raises endometrial cancer risk by 2- to 12-fold depending on duration. [4][30] Common progestogen combinations used alongside oral estradiol include micronized progesterone 100 to 200 mg nightly or medroxyprogesterone acetate 2.5 mg daily.

Contraindications per the FDA label include: known, suspected, or history of breast cancer; known or suspected estrogen-dependent neoplasia; active or history of deep vein thrombosis or pulmonary embolism; active or recent arterial thromboembolic disease; known anaphylactic reaction or angioedema to estradiol; known liver impairment or disease; known protein C, protein S, or antithrombin deficiency; and known or suspected pregnancy. [3]

Bone density benefit: a meta-analysis of 57 randomized trials (Cochrane, 2017, N=11,068) found that estrogen-containing hormone therapy reduced the relative risk of vertebral fracture by 35% and non-vertebral fracture by 27% compared to placebo. [31] Arkansas has a higher-than-national-average rate of osteoporosis-related hospitalizations among women over 65, making this data point particularly relevant for prescribers in the state. [32]

Monitoring Oral Estradiol Therapy in Arkansas

After initiating oral estradiol, standard monitoring includes a follow-up visit at 8 to 12 weeks to assess symptom response, side effects, and any emerging contraindications. Annual monitoring should include blood pressure measurement, breast examination, and review of the continued need for therapy. [9]

Serum estradiol levels are not routinely required for standard-dose oral therapy, but may be checked at 4 to 6 weeks when titrating or when symptoms remain uncontrolled at 2 mg daily. Target serum estradiol for symptom control is generally 40 to 100 pg/mL, though individual response varies. [33] Endometrial surveillance (transvaginal ultrasound) is indicated for any unscheduled vaginal bleeding in women on hormone therapy. [34]

Drug interactions worth flagging for Arkansas prescribers: St. John's Wort (common in over-the-counter supplements sold in Arkansas health food stores) is a potent CYP3A4 inducer that can reduce estradiol plasma levels by 35 to 40%. [26] Clarithromycin and other CYP3A4 inhibitors may increase estradiol exposure. Patients should disclose all supplements and antibiotics at each visit.

A baseline lipid panel is appropriate for patients with cardiovascular risk factors, given oral estradiol's differential effect on LDL (slight decrease), HDL (modest increase), and triglycerides (potential increase of 15 to 25%). [27] Repeat lipid testing at 6 months is reasonable for patients with baseline hypertriglyceridemia above 200 mg/dL before committing to long-term oral therapy. Consider transdermal estradiol as the preferred route in that subgroup.